Osteoporosis International

, Volume 20, Issue 1, pp 151–159 | Cite as

Zoledronate reverses mandibular bone loss in osteoprotegerin-deficient mice

  • Z.-F. Sheng
  • K. Xu
  • Y.-L. Ma
  • J.-H. Liu
  • R.-C. Dai
  • Y.-H. Zhang
  • Y.-B. Jiang
  • E.-Y. Liao
Original Article

Abstract

Summary

To characterize the changes in osteoprotegerin-deficient (OPG−/−) mice mandibles and the possible mandibular bone loss prevention by zoledronate. This preventive effect in the mandible differed from that in the proximal tibia and was independent of the OPG pathway.

Introduction

The study aimed to characterize both the changes in the mandible in osteoprotegerin-deficient (OPG−/−) mice and possible mandibular bone loss prevention by zoledronate.

Methods

Twenty-eight 6-week-old female mice (C57BL/6J), including OPG−/− (n = 21) and wild-type (WT) (n = 7) mice, were assigned to four groups after 2 weeks of acclimatization to local vivarium conditions: wild mice with vehicle (WT group); OPG−/− mice with vehicle (OPG−/− group); and OPG−/− mice that were subcutaneously injected with either 50 or 150 μg/kg zoledronate (Zol-50 and Zol-150 groups, respectively). Mice were sacrificed at 4 weeks after these treatments and after fasting for 12 h. Sera were harvested for biochemical analyses. The right mandible and tibia of each mouse were selected for microCT analysis. Student’s t-test was performed for comparisons of bone parameters at different sites in the WT group. Analysis of variance (ANOVA) was used to compare the biomarkers and bone parameters in the different treatment groups.

Results

Serum bone-specific alkaline phosphatase (B-ALP) and tartrate-resistant acid phosphatase 5b (TRACP-5b) were significantly decreased in WT mice as compared to the levels in the OPG−/− mice (P < 0.05). Zoledronate treatment decreased the high serum B-ALP activity observed in OPG−/− mice to the levels seen in WT mice, while serum TRACP-5b concentrations were decreased to levels even lower than those in WT mice. There were substantial variations in BMD and microstructure of the mandibular and proximal tibial trabeculae. Mandibular bone loss was less affected by OPG gene deprivation than the proximal tibia was. Both zoledronate groups showed greater BMD, trabecular BV/TV, Tb.Th, Tb.N, and Conn.D and a significant decrease in Tb.Sp and SMI as compared to the findings in OPG−/− mice (P < 0.05). However, higher apparent BMD and more compact plate-like trabeculae were observed in the mandible after treatment with zoledronate as compared to the findings in the proximal tibia. No significant differences were found in any parameter in both zoledronate groups.

Conclusions

The present study showed that zoledronate could reverse the significant bone loss in mice mandibles that was induced by OPG gene deficiency. This preventive effect, which was accompanied with considerable inhibition of bone turnover, differed in the mandible and in the proximal tibia and was independent of the OPG pathway.

Keywords

Bisphosphonate BMD Mandible MicroCT Microstructure Osteoprotegerin-deficient mice 

References

  1. 1.
    Felsenberg D, Boonen S (2005) The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther 27:1–11PubMedCrossRefGoogle Scholar
  2. 2.
    Turner CH (2002) Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int 13:97–104PubMedCrossRefGoogle Scholar
  3. 3.
    Jeffcoat M (2005) The association between osteoporosis and oral bone loss. J Periodontol 76(Suppl):2125–2132PubMedCrossRefGoogle Scholar
  4. 4.
    Krall EA, Garcia RI, Dawson-Hughes B (1996) Increased risk of tooth loss is related to bone loss at the whole body, hip, and spine. Calcif Tissue Int 59:433–437PubMedCrossRefGoogle Scholar
  5. 5.
    Taguchi A, Tanimoto K, Suei Y, Wada T (1995) Tooth loss and mandibular osteopenia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 79:127–132PubMedCrossRefGoogle Scholar
  6. 6.
    Kribbs PJ (1990) Comparison of mandibular bone in normal and osteoporotic women. J Prosthet Dent 63:218–222PubMedCrossRefGoogle Scholar
  7. 7.
    Payne JB, Reinhardt RA, Nummikoski PV, Patil KD (1999) Longitudinal alveolar bone loss in postmenopausal osteoporotic/osteopenic women. Osteoporos Int 10:34–40PubMedCrossRefGoogle Scholar
  8. 8.
    Taguchi A, Tanimoto K, Suei Y, Otani K, Wada T (1995) Oral signs as indicators of possible osteoporosis in elderly women. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 80:612–616PubMedCrossRefGoogle Scholar
  9. 9.
    Taguchi A, Sanada M, Krall E, Nakamoto T, Ohtsuka M, Suei Y, Tanimoto K, Kodama I, Tsuda M, Ohama K (2003) Relationship between dental panoramic radiographic findings and biochemical markers of bone turnover. J Bone Miner Res 18:1689–1694PubMedCrossRefGoogle Scholar
  10. 10.
    Simonet WS, Lacey DL, Danstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997) Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89:309–319PubMedCrossRefGoogle Scholar
  11. 11.
    Kong YY, Yoshida H, Sarosi L, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM (1999) OPGL is a key regulation of osteoclastogenesis, lymphocyte development and lymphnode organogensis. Nature 397:315–323PubMedCrossRefGoogle Scholar
  12. 12.
    Teitelbaum SL (2000) Bone resorption by osteoclasts. Science 289:1504–1508PubMedCrossRefGoogle Scholar
  13. 13.
    Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL (2000) The role of osteoprotegerin and osteoprotegrin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15:2–12PubMedCrossRefGoogle Scholar
  14. 14.
    Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260–1268PubMedCrossRefGoogle Scholar
  15. 15.
    Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, Ozawa H (1998) Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 29(247):610–615CrossRefGoogle Scholar
  16. 16.
    Nakamura M, Udagawa N, Matsuura S, Mogi M, Nakamura H, Horiuchi H, Saito N, Hiraoka BY, Kobayashi Y, Takaoka K, Ozawa H, Miyazawa H, Takahashi N (2003) Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 144:5441–5449PubMedCrossRefGoogle Scholar
  17. 17.
    Jiang G, Matsumoto H, Yamane J, Kuboyama N, Akimoto Y, Fujii A (2004) Prevention of trabecular bone loss in the mandible of ovariectomized rats. J Oral Sci 46:75–85PubMedCrossRefGoogle Scholar
  18. 18.
    Kimura E, Nishioka T, Hasegawa K, Maki K (2007) Effects of bisphosphonate on the mandible of rats in the growing phase with steroid-induced osteoporosis. Oral Dis 13:544–549PubMedCrossRefGoogle Scholar
  19. 19.
    Srisubut S, Teerakapong A, Vattraphodes T, Taweechaisupapong S (2007) Effect of local delivery of alendronate on bone formation in bioactive glass grafting in rats. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 10:e11–e16CrossRefGoogle Scholar
  20. 20.
    Li EC, Davis LE (2003) Zoledronic acid: a new parenteral bisphosphonate. Clin Ther 25:2669–2708PubMedCrossRefGoogle Scholar
  21. 21.
    Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, Spelsberg TC (2000) Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 60:6001–6007PubMedGoogle Scholar
  22. 22.
    Green JR (2001) Chemical and biological prerequisites for novel bisphosphonate molecules: Results of comparative preclinical studies. Semin Oncol 28(Suppl):4–10PubMedCrossRefGoogle Scholar
  23. 23.
    Mavropoulos A, Rizzoli R, Ammann P (2007) Different responsiveness of alveolar and tibial bone to bone loss stimuli. J Bone Miner Res 22:403–410PubMedCrossRefGoogle Scholar
  24. 24.
    Yamashiro T, Takano-Yamamoto T (1998) Differential responses of mandibular condyle and femur to oestrogen deficiency in young rats. Arch Oral Biol 43:191–195PubMedCrossRefGoogle Scholar
  25. 25.
    Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, Ozawa H (1998) Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247:610–615PubMedCrossRefGoogle Scholar
  26. 26.
    Tommasini SM, Morgan TG, van der Meulen MCh, Jepsen KJ (2005) Genetic variation in structure-function relationships for the inbred mouse lumbar vertebral body. J Bone Miner Res 20:817–827PubMedCrossRefGoogle Scholar
  27. 27.
    Sheng ZF, Dai RC, Wu XP, Fang LN, Fan HJ, Liao EY (2007) Regionally specific compensation for bone loss in the tibial trabeculae of estrogen-deficient rats. Acta Radiol 48:531–539PubMedCrossRefGoogle Scholar
  28. 28.
    Jiang G, Matsumoto H, Fujii A (2003) Mandible bone loss in osteoporosis rats. J Bone Miner Metab 21:388–395PubMedCrossRefGoogle Scholar
  29. 29.
    Mavropoulos A, Kiliaridis S, Bresin A, Ammann P (2004) Effect of different masticatory functional and mechanical demands on the structural adaptation of the mandibular alveolar bone in young growing rats. Bone 35:191–197PubMedCrossRefGoogle Scholar
  30. 30.
    Green JR (2004) Bisphosphonates: preclinical review. Oncologist 9(Suppl):3–13PubMedCrossRefGoogle Scholar
  31. 31.
    Yong Hee K, Gwan-shik K, Jeong-Hwa B (2002) Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. Exp Mol Med 34:145–151Google Scholar
  32. 32.
    Mackie PS, Fisher JL, Zhou H, Choong PF (2001) Bisphosphonates regulate cell growth and gene expression in the UMR 106–01 clonal rat osteosarcoma cell line. Br J Cancer 84:951–958PubMedCrossRefGoogle Scholar
  33. 33.
    Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Gründker C, Hofbauer LC (2002) Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 291:680–686PubMedCrossRefGoogle Scholar
  34. 34.
    Pan B, Farrugia AN, To LB, Findlay DM, Green J, Lynch K, Zannettino AC (2004) The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). J Bone Miner Res 19:147–154PubMedCrossRefGoogle Scholar
  35. 35.
    Rhee Y, Won YY, Baek MH, Lim SK (2004) Maintenance of increased bone mass after recombinant human parathyroid hormone (1–84) with sequential zoledronate treatment in ovariectomized rats. J Bone Miner Res 19:931–937PubMedCrossRefGoogle Scholar
  36. 36.
    Glatt M, Pataki A, Evans GP, Hornby SB, Green JR (2004) Loss of vertebral bone and mechanical strength in estrogen-deficient rats is prevented by long-term administration of zoledronic acid. Osteoporos Int 15:707–715PubMedCrossRefGoogle Scholar
  37. 37.
    Marx RE, Cillo JE Jr, Ulloa JJ (2007) Oral Bisphosphonate-Induced Osteonecrosis: Risk Factors, Prediction of Risk Using Serum CTX Testing, Prevention, and Treatment. J Oral Maxillofac Surg 65:2397–2410PubMedCrossRefGoogle Scholar
  38. 38.
    Dannemann C, Grätz KW, Riener MO, Zwahlen RA (2007) Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder. Bone 40:828–834PubMedCrossRefGoogle Scholar
  39. 39.
    Durie BG, Katz M, Crowley J (2005) Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353:99–102 discussion 99–102PubMedCrossRefGoogle Scholar
  40. 40.
    Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580–8587PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2008

Authors and Affiliations

  • Z.-F. Sheng
    • 1
  • K. Xu
    • 1
  • Y.-L. Ma
    • 1
  • J.-H. Liu
    • 2
  • R.-C. Dai
    • 1
  • Y.-H. Zhang
    • 1
  • Y.-B. Jiang
    • 3
  • E.-Y. Liao
    • 1
  1. 1.Institute of Metabolism and EndocrinologyThe Second Xiang-Ya Hospital, Central South UniversityChangshaPeople’s Republic of China
  2. 2.Department of Metabolism and EndocrinologyThe First Affiliated Hospital of Nanhua UniversityHengyangPeople’s Republic of China
  3. 3.Osteoporosis and Arthritis Lab and Division of Musculoskeletal Radiology, Department of RadiologyUniversity of MichiganMichiganUSA

Personalised recommendations